The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer relapse
Author:
Publisher
Springer Science and Business Media LLC
Subject
Surgery
Link
http://link.springer.com/content/pdf/10.1007/s13304-013-0229-9.pdf
Reference54 articles.
1. Yancik R (1993) EOC: age contrast in incidence, histology, disease stage at diagnosis, and mortality. Cancer 71(2 Suppl):517–523
2. McGuire WP, Hoskin WJ, Brady MF et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV EOC. N Engl J Med 334:1–6
3. Ozolos RF, Bundy BN, Greer BE et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:194–200
4. Ozolos RF, Young RC (1988) Epithelial ovarian cancer. Curr Probl Cancer 11:57–122
5. Leitao MM Jr, Chi DS (2009) Surgical management of recurrent ovarian cancer. Semin Oncol 36:106–111
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Predictors of morbidity and mortality in patients submitted to cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for ovarian carcinomatosis: a multicenter study;Pleura and Peritoneum;2020-12-04
2. Rosiglitazone ameliorates senescence and promotes apoptosis in ovarian cancer induced by olaparib;Cancer Chemotherapy and Pharmacology;2020-01-06
3. Intraperitoneal Chemotherapy in Ovarian Cancer;Journal of Obstetrics, Gynecology and Cancer Research;2017-12-01
4. Evaluation of cisplatin plasma levels in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy;Acta Chirurgica Belgica;2016-01-02
5. Consequences of defensive medicine, second victims, and clinical-judicial syndrome on surgeons’ medical practice and on health service;Updates in Surgery;2015-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3